{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T18:57:58Z","timestamp":1787165878842,"version":"build-2736575974"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T00:00:00Z","timestamp":1724716800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T00:00:00Z","timestamp":1724716800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetol Metab Syndr"],"DOI":"10.1186\/s13098-024-01446-1","type":"journal-article","created":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T00:02:24Z","timestamp":1724716944000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Effect of SGLT-2 inhibitors on acute kidney injury in patients with heart failure: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"16","author":[{"given":"Xianghong","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meihong","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donghua","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuanchuan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyun","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,27]]},"reference":[{"issue":"10120","key":"1446_CR1","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/S0140-6736(17)32520-5","volume":"391","author":"N Conrad","year":"2018","unstructured":"Conrad N, et al. Temporal trends and patterns in heart failure incidence: a population-based study of 4 million individuals. Lancet. 2018;391(10120):572\u201380.","journal-title":"Lancet"},{"issue":"15","key":"1446_CR2","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","volume":"383","author":"M Packer","year":"2020","unstructured":"Packer M, et al. Cardiovascular and renal outcomes with Empagliflozin in Heart failure. N Engl J Med. 2020;383(15):1413\u201324.","journal-title":"N Engl J Med"},{"issue":"21","key":"1446_CR3","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JJV McMurray","year":"2019","unstructured":"McMurray JJV, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995\u20132008.","journal-title":"N Engl J Med"},{"issue":"12","key":"1446_CR4","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","volume":"387","author":"SD Solomon","year":"2022","unstructured":"Solomon SD, et al. Dapagliflozin in Heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2022;387(12):1089\u201398.","journal-title":"N Engl J Med"},{"issue":"16","key":"1446_CR5","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","volume":"385","author":"SD Anker","year":"2021","unstructured":"Anker SD, et al. Empagliflozin in Heart failure with a preserved ejection fraction. N Engl J Med. 2021;385(16):1451\u201361.","journal-title":"N Engl J Med"},{"issue":"4","key":"1446_CR6","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1002\/ejhf.1713","volume":"22","author":"K Damman","year":"2020","unstructured":"Damman K, et al. Randomized, double-blind, placebo-controlled, multicentre pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure (EMPA-RESPONSE-AHF). Eur J Heart Fail. 2020;22(4):713\u201322.","journal-title":"Eur J Heart Fail"},{"issue":"2","key":"1446_CR7","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2030183","volume":"384","author":"DL Bhatt","year":"2021","unstructured":"Bhatt DL, et al. Sotagliflozin in patients with diabetes and recent worsening heart failure. N Engl J Med. 2021;384(2):117\u201328.","journal-title":"N Engl J Med"},{"issue":"14","key":"1446_CR8","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1001\/jama.2020.1906","volume":"323","author":"MC Petrie","year":"2020","unstructured":"Petrie MC, et al. Effect of Dapagliflozin on worsening heart failure and Cardiovascular Death in patients with heart failure with and without diabetes. JAMA. 2020;323(14):1353\u201368.","journal-title":"JAMA"},{"issue":"15","key":"1446_CR9","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1161\/CIRCULATIONAHA.121.054669","volume":"144","author":"SD Anker","year":"2021","unstructured":"Anker SD, et al. Kidney function after initiation and discontinuation of Empagliflozin in patients with heart failure with and without type 2 diabetes: insights from the EMPERIAL trials. Circulation. 2021;144(15):1265\u20137.","journal-title":"Circulation"},{"issue":"10","key":"1446_CR10","doi-asserted-by":"publisher","first-page":"e010080","DOI":"10.1161\/CIRCHEARTFAILURE.122.010080","volume":"15","author":"A Peikert","year":"2022","unstructured":"Peikert A, et al. Efficacy and safety of Dapagliflozin in Heart failure with mildly reduced or preserved ejection Fraction according to age: the DELIVER Trial. Circ Heart Fail. 2022;15(10):e010080.","journal-title":"Circ Heart Fail"},{"issue":"6","key":"1446_CR11","doi-asserted-by":"publisher","first-page":"820","DOI":"10.7326\/M21-4776","volume":"175","author":"JH Butt","year":"2022","unstructured":"Butt JH, et al. Efficacy and safety of Dapagliflozin according to Frailty in Heart failure with reduced ejection fraction: a Post Hoc Analysis of the DAPA-HF trial. Ann Intern Med. 2022;175(6):820\u201330.","journal-title":"Ann Intern Med"},{"issue":"7","key":"1446_CR12","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1001\/jamacardio.2023.1090","volume":"8","author":"J Butler","year":"2023","unstructured":"Butler J, et al. Safety and Efficacy of Empagliflozin and Diuretic Use in patients with heart failure and preserved ejection fraction: a Post Hoc Analysis of the EMPEROR-Preserved trial. JAMA Cardiol. 2023;8(7):640\u20139.","journal-title":"JAMA Cardiol"},{"key":"1446_CR13","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.","journal-title":"BMJ"},{"key":"1446_CR14","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JP Higgins","year":"2011","unstructured":"Higgins JP, et al. The Cochrane collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.","journal-title":"BMJ"},{"issue":"7650","key":"1446_CR15","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","volume":"336","author":"GH Guyatt","year":"2008","unstructured":"Guyatt GH, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336(7650):924\u20136.","journal-title":"BMJ"},{"issue":"11","key":"1446_CR16","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1161\/CIRCULATIONAHA.123.065061","volume":"149","author":"JJV McMurray","year":"2024","unstructured":"McMurray JJV, et al. Effect of Dapagliflozin Versus placebo on symptoms and 6-Minute Walk Distance in patients with heart failure: the DETERMINE Randomized clinical trials. Circulation. 2024;149(11):825\u201338.","journal-title":"Circulation"},{"issue":"11","key":"1446_CR17","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1038\/s41591-021-01536-x","volume":"27","author":"ME Nassif","year":"2021","unstructured":"Nassif ME, et al. The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial. Nat Med. 2021;27(11):1954\u201360.","journal-title":"Nat Med"},{"issue":"18","key":"1446_CR18","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1161\/CIRCULATIONAHA.119.042929","volume":"140","author":"ME Nassif","year":"2019","unstructured":"Nassif ME, et al. Dapagliflozin effects on biomarkers, symptoms, and functional status in patients with heart failure with reduced ejection fraction: the DEFINE-HF Trial. Circulation. 2019;140(18):1463\u201376.","journal-title":"Circulation"},{"issue":"7","key":"1446_CR19","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1002\/ejhf.1486","volume":"21","author":"WT Abraham","year":"2019","unstructured":"Abraham WT, et al. Rationale and design of the EMPERIAL-Preserved and EMPERIAL-Reduced trials of empagliflozin in patients with chronic heart failure. Eur J Heart Fail. 2019;21(7):932\u201342.","journal-title":"Eur J Heart Fail"},{"issue":"6","key":"1446_CR20","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1161\/CIRCULATIONAHA.120.052186","volume":"143","author":"MMY Lee","year":"2021","unstructured":"Lee MMY, et al. Effect of Empagliflozin on Left ventricular volumes in patients with type 2 diabetes, or Prediabetes, and heart failure with reduced ejection fraction (SUGAR-DM-HF). Circulation. 2021;143(6):516\u201325.","journal-title":"Circulation"},{"issue":"1","key":"1446_CR21","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1001\/jamacardio.2022.4210","volume":"8","author":"FR Mc Causland","year":"2023","unstructured":"Mc Causland FR, et al. Dapagliflozin and kidney outcomes in patients with heart failure with mildly reduced or preserved ejection fraction: a prespecified analysis of the DELIVER Randomized Clinical Trial. JAMA Cardiol. 2023;8(1):56\u201365.","journal-title":"JAMA Cardiol"},{"issue":"1","key":"1446_CR22","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.cardfail.2022.09.009","volume":"29","author":"SN Voorrips","year":"2023","unstructured":"Voorrips SN, et al. Longitudinal changes in circulating ketone body levels in patients with Acute Heart failure: a Post Hoc Analysis of the EMPA-Response-AHF trial. J Card Fail. 2023;29(1):33\u201341.","journal-title":"J Card Fail"},{"issue":"4","key":"1446_CR23","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1161\/CIRCULATIONAHA.122.059725","volume":"146","author":"MN Kosiborod","year":"2022","unstructured":"Kosiborod MN, et al. Effects of Empagliflozin on symptoms, Physical limitations, and quality of life in patients hospitalized for Acute Heart failure: results from the EMPULSE Trial. Circulation. 2022;146(4):279\u201388.","journal-title":"Circulation"},{"issue":"4","key":"1446_CR24","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1038\/s41591-022-01703-8","volume":"28","author":"JA Spertus","year":"2022","unstructured":"Spertus JA, et al. The SGLT2 inhibitor canagliflozin in heart failure: the CHIEF-HF remote, patient-centered randomized trial. Nat Med. 2022;28(4):809\u201313.","journal-title":"Nat Med"},{"issue":"17","key":"1446_CR25","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1161\/CIRCULATIONAHA.120.052503","volume":"143","author":"ME Nassif","year":"2021","unstructured":"Nassif ME, et al. Empagliflozin effects on Pulmonary Artery pressure in patients with heart failure: results from the EMBRACE-HF trial. Circulation. 2021;143(17):1673\u201386.","journal-title":"Circulation"},{"issue":"9","key":"1446_CR26","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1002\/ejhf.2584","volume":"24","author":"D Vukadinovic","year":"2022","unstructured":"Vukadinovic D, et al. Side effects and treatment initiation barriers of sodium-glucose cotransporter 2 inhibitors in heart failure: a systematic review and meta-analysis. Eur J Heart Fail. 2022;24(9):1625\u201332.","journal-title":"Eur J Heart Fail"},{"issue":"12","key":"1446_CR27","doi-asserted-by":"publisher","first-page":"e1002983","DOI":"10.1371\/journal.pmed.1002983","volume":"16","author":"J Menne","year":"2019","unstructured":"Menne J, et al. Acute kidney injury and adverse renal events in patients receiving SGLT2-inhibitors: a systematic review and meta-analysis. PLoS Med. 2019;16(12):e1002983.","journal-title":"PLoS Med"},{"issue":"10365","key":"1446_CR28","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1016\/S0140-6736(22)02074-8","volume":"400","author":"SiM-AC-RT Consortium","year":"2022","unstructured":"Nuffield Department of Population Health Renal Studies, G. and, Consortium SiM-AC-RT. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. Lancet. 2022;400(10365):1788\u2013801.","journal-title":"Lancet"},{"issue":"8 Pt 1","key":"1446_CR29","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/j.jchf.2023.05.026","volume":"11","author":"B Pitt","year":"2023","unstructured":"Pitt B, et al. Effect of Sotagliflozin on early mortality and heart failure-related events: a Post Hoc Analysis of SOLOIST-WHF. JACC Heart Fail. 2023;11(8 Pt 1):879\u201389.","journal-title":"JACC Heart Fail"},{"issue":"10","key":"1446_CR30","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.1002\/ejhf.2681","volume":"24","author":"AA Voors","year":"2022","unstructured":"Voors AA, et al. Renal effects of empagliflozin in patients hospitalized for acute heart failure: from the EMPULSE trial. Eur J Heart Fail. 2022;24(10):1844\u201352.","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"1446_CR31","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s12933-022-01455-2","volume":"21","author":"HM Salah","year":"2022","unstructured":"Salah HM, et al. Efficacy and safety of sodium-glucose cotransporter 2 inhibitors initiation in patients with acute heart failure, with and without type 2 diabetes: a systematic review and meta-analysis. Cardiovasc Diabetol. 2022;21(1):20.","journal-title":"Cardiovasc Diabetol"},{"issue":"4","key":"1446_CR32","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1161\/CIRCULATIONAHA.120.050391","volume":"143","author":"PS Jhund","year":"2021","unstructured":"Jhund PS, et al. Efficacy of Dapagliflozin on renal function and outcomes in patients with heart failure with reduced ejection fraction: results of DAPA-HF. Circulation. 2021;143(4):298\u2013309.","journal-title":"Circulation"},{"issue":"7","key":"1446_CR33","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1002\/ejhf.2915","volume":"25","author":"S Chatur","year":"2023","unstructured":"Chatur S, et al. Renal and blood pressure effects of dapagliflozin in recently hospitalized patients with heart failure with mildly reduced or preserved ejection fraction: insights from the DELIVER trial. Eur J Heart Fail. 2023;25(7):1170\u20135.","journal-title":"Eur J Heart Fail"},{"issue":"10254","key":"1446_CR34","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/S0140-6736(20)31824-9","volume":"396","author":"F Zannad","year":"2020","unstructured":"Zannad F, et al. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. Lancet. 2020;396(10254):819\u201329.","journal-title":"Lancet"},{"issue":"7","key":"1446_CR35","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1093\/eurjhf\/hft028","volume":"15","author":"V Lazzarini","year":"2013","unstructured":"Lazzarini V, et al. Heart failure in elderly patients: distinctive features and unresolved issues. Eur J Heart Fail. 2013;15(7):717\u201323.","journal-title":"Eur J Heart Fail"},{"issue":"6","key":"1446_CR36","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1002\/ejhf.2483","volume":"24","author":"D Stolfo","year":"2022","unstructured":"Stolfo D, et al. Use of evidence-based therapy in heart failure with reduced ejection fraction across age strata. Eur J Heart Fail. 2022;24(6):1047\u201362.","journal-title":"Eur J Heart Fail"},{"issue":"36","key":"1446_CR37","doi-asserted-by":"publisher","first-page":"3402","DOI":"10.1093\/eurheartj\/ehaa496","volume":"41","author":"M Serenelli","year":"2020","unstructured":"Serenelli M, et al. Effect of dapagliflozin according to baseline systolic blood pressure in the Dapagliflozin and Prevention of adverse outcomes in heart failure trial (DAPA-HF). Eur Heart J. 2020;41(36):3402\u201318.","journal-title":"Eur Heart J"},{"issue":"9","key":"1446_CR38","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1097\/HJH.0000000000002492","volume":"38","author":"M Bohm","year":"2020","unstructured":"Bohm M, et al. Heart failure and renal outcomes according to baseline and achieved blood pressure in patients with type 2 diabetes: results from EMPA-REG OUTCOME. J Hypertens. 2020;38(9):1829\u201340.","journal-title":"J Hypertens"},{"issue":"4","key":"1446_CR39","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.jacc.2021.05.002","volume":"78","author":"RB Patel","year":"2021","unstructured":"Patel RB, et al. Kidney function and outcomes in patients hospitalized with heart failure. J Am Coll Cardiol. 2021;78(4):330\u201343.","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"1446_CR40","doi-asserted-by":"publisher","first-page":"356","DOI":"10.2337\/dc17-1096","volume":"41","author":"SE Inzucchi","year":"2018","unstructured":"Inzucchi SE, et al. How does Empagliflozin reduce Cardiovascular Mortality? Insights from a mediation analysis of the EMPA-REG OUTCOME Trial. Diabetes Care. 2018;41(2):356\u201363.","journal-title":"Diabetes Care"},{"issue":"6","key":"1446_CR41","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/j.jacbts.2020.02.004","volume":"5","author":"GD Lopaschuk","year":"2020","unstructured":"Lopaschuk GD, Verma S. Mechanisms of Cardiovascular benefits of Sodium glucose co-transporter 2 (SGLT2) inhibitors: a state-of-the-art review. JACC Basic Transl Sci. 2020;5(6):632\u201344.","journal-title":"JACC Basic Transl Sci"},{"issue":"15","key":"1446_CR42","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.2169\/internalmedicine.9842-17","volume":"57","author":"M Ito","year":"2018","unstructured":"Ito M, Tanaka T. The Anticipated Renoprotective effects of Sodium-glucose cotransporter 2 inhibitors. Intern Med. 2018;57(15):2105\u201314.","journal-title":"Intern Med"},{"issue":"8","key":"1446_CR43","doi-asserted-by":"publisher","first-page":"1988","DOI":"10.1111\/dom.13301","volume":"20","author":"CCJ Dekkers","year":"2018","unstructured":"Dekkers CCJ, et al. Effects of the SGLT-2 inhibitor dapagliflozin on glomerular and tubular injury markers. Diabetes Obes Metab. 2018;20(8):1988\u201393.","journal-title":"Diabetes Obes Metab"}],"container-title":["Diabetology & Metabolic Syndrome"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13098-024-01446-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13098-024-01446-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13098-024-01446-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T01:04:30Z","timestamp":1724720670000},"score":1,"resource":{"primary":{"URL":"https:\/\/dmsjournal.biomedcentral.com\/articles\/10.1186\/s13098-024-01446-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,27]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1446"],"URL":"https:\/\/doi.org\/10.1186\/s13098-024-01446-1","relation":{},"ISSN":["1758-5996"],"issn-type":[{"value":"1758-5996","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,27]]},"assertion":[{"value":"6 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"207"}}